Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.42 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788959 | 0.91 | MDM4 (0.47) | MDM4TP53CASP3SLC17A5 | |
| SCHEMBL22738558 | 0.91 | MDM4 (0.45) | MDM4TP53CASP3SLC17A5 | |
| SCHEMBL589006 | 0.86 | KMT2A (0.45) | MDM4TP53CASP3 | |
| SCHEMBL13253077 | 0.85 | CASP3 (0.48) | MDM4TP53CASP3SLC17A5 | |
| SCHEMBL5051746 | 0.85 | MDM4 (0.45) | MDM4TP53CASP3 | |
| SCHEMBL30480131 | 0.85 | FDFT1 (0.49) | MDM4TP53CASP3 | |
| SCHEMBL12369385 | 0.85 | TLR2 (0.39) | MDM4TP53 | |
| SCHEMBL10020438 | 0.84 | MDM4 (0.54) | MDM4TP53CASP3SLC17A5 | |
| SCHEMBL1739174 | 0.84 | MDM4 (0.54) | MDM4TP53CASP3SLC17A5 | |
| SCHEMBL23125122 | 0.84 | MDM4 (0.46) | MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040340-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040340-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040340-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-16 | — | — | US | disclosed |
| US-8114973-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114973-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8114973-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2012-02-14 | — | — | US | disclosed |
| US-8071755-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071755-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071755-B2 | Nucleotide analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2011-12-06 | — | — | US | disclosed |
| US-7994304-B2 | Sequencing nucleic acid molecules; promote accurate base-over-base incorporation in sequencing-by-synthesis reactions, resulting in greater read lengths | HELICOS BIOSCIENCES CORPORATION (US) | 2011-08-09 | — | — | US | disclosed |
| WO-2009124254-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009124254-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2009-10-08 | — | — | WO | disclosed |
| US-20090186351-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186351-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186351-A1 | NUCLEOTIDE ANALOGS | HELICOS BIOSCIENCES CORPORATION (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090061437-A1 | Nucleotide Analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090061437-A1 | Nucleotide Analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20090061437-A1 | Nucleotide Analogs | HELICOS BIOSCIENCES CORPORATION (US) | 2009-03-05 | — | — | US | disclosed |
| US-20080227970-A1 | Methods And Compositions For Sequencing A Nucleic Acid | HELICOS BIOSCIENCES CORPORATION (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080103053-A1 | Methods and compositions for sequencing a nucleic acid | HELICOS BIOSCIENCES CORPORATION (US) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040340-A1 | NUCLEOTIDE ANALOGS | NT5C3B, RNGTT, NT5C2 | MDM4 383/4885TP53 1138/4885CASP3 4828/4885 |
| US-20080227970-A1 | Methods And Compositions For Sequencing A Nucleic Acid | RNGTT, NT5C3B, POLN | MDM4 886/4885TP53 2047/4885CASP3 4830/4885 |
| US-20090186351-A1 | NUCLEOTIDE ANALOGS | NT5C3B, RNGTT, NT5C2 | MDM4 383/4885TP53 1138/4885CASP3 4828/4885 |
| US-20080103053-A1 | Methods and compositions for sequencing a nucleic acid | RNGTT, NT5C3B, POLN | MDM4 886/4885TP53 2047/4885CASP3 4830/4885 |
| US-20090061437-A1 | Nucleotide Analogs | NT5C3B, RNGTT, NT5C2 | MDM4 383/4885TP53 1138/4885CASP3 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.